Basic and Translational Disparities Research Funding

CRCHD supports the following basic and translational research funding opportunities to increase scientific understanding of cancer as well as reduce cancer health disparities.

Basic Cancer Biology Research

Basic cancer research focuses on biological mechanisms related to cancer.

CRCHD offers two funding opportunities which focus on investigating biological variations across racially and ethnically diverse populations that may contribute to cancer disparities directly or in conjunction with environmental exposures.

A third opportunity focuses broadly on advancing cancer research while promoting diversity of the health-related research workforce.

Title & CRCHD Contact	Application Due Date & Purpose
Basic Cancer Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) Dr. Tiffany Wallace 240-276-5114	Due Dates: June 19, 2018; November 19, 2018; June 18, 2019; November 19, 2019; June 18, 2020; November 19, 2020, February 8, 2021 Supports basic research innovative studies designed to investigate biological/genetic bases of cancer disparities. *Note: Early-stage investigators who receive an R01 award are eligible to have their grant transitioned to an R37 award and, as a result, have the opportunity to have their funding extended by up to two years. Learn more about the R37 award.
Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) Dr. Tiffany Wallace 240-276-5114	Due Dates: June 19 2018; November 19, 2018; June 18, 2019; November 19, 2019; June 18, 2020; November 19, 2020, February 18, 2021 Supports basic research pilot and feasibility studies on the biological/genetic causes and mechanisms of cancer health disparities.
Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21) Dr. John Ojeifo (240) 276-6186	Due Dates: June 18 and November 19 Supports eligible investigators from underrepresented groups to conduct research projects focused on the basic biology of cancer. Fact Sheet

Title & CRCHD Contact

Application Due Date & Purpose

Basic Cancer Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)

Dr. Tiffany Wallace
240-276-5114

Due Dates: June 19, 2018; November 19, 2018; June 18, 2019; November 19, 2019; June 18, 2020; November 19, 2020, February 8, 2021

Supports basic research innovative studies designed to investigate biological/genetic bases of cancer disparities.

*Note: Early-stage investigators who receive an R01 award are eligible to have their grant transitioned to an R37 award and, as a result, have the opportunity to have their funding extended by up to two years. Learn more about the R37 award.

Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)

Dr. Tiffany Wallace
240-276-5114

Due Dates: June 19 2018; November 19, 2018; June 18, 2019; November 19, 2019; June 18, 2020; November 19, 2020, February 18, 2021

Supports basic research pilot and feasibility studies on the biological/genetic causes and mechanisms of cancer health disparities.

Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21)

Dr. John Ojeifo
(240) 276-6186

Due Dates: June 18 and November 19

Supports eligible investigators from underrepresented groups to conduct research projects focused on the basic biology of cancer.

Fact Sheet

Translational Cancer Research

Translational research focuses on moving basic research findings into the clinic to advance cancer therapy.

CRCHD offers the following translational research funding opportunities which focus on reducing cancer health disparities.

Title & CRCHD Contact	Application Due Date & Purpose
Minority Patient-Derived Xenograft (PDX) Development and Trial Centers (M-PDTCs) (U54) Dr. Tiffany Wallace 240-276-5114	Due Date: January 18, 2018 Solicits applications for Minority PDX Development and Trial Centers (M-PDTCs) to join the PDTC Research Network (PDXNet) to expand and diversify the PDXNet. These M-PDTCs will develop and conduct pre-clinical testing of models derived from racial/ethnic minority populations.
Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional) Dr. Tiffany Wallace 240-276-5114 Download Technical Assistance Webinar Slides	Due Dates: June 19, 2019, October 18, 2019, June 19, 2020, and October 18, 2020 Supports feasibility and planning activities to develop translational research programs focused on cancer health disparities research with the expectation that the research programs will become competitive for a full Specialized Programs of Research Excellence (SPORE) award.

Title & CRCHD Contact

Application Due Date & Purpose

Minority Patient-Derived Xenograft (PDX) Development and Trial Centers (M-PDTCs) (U54)

Dr. Tiffany Wallace
240-276-5114

Due Date: January 18, 2018

Solicits applications for Minority PDX Development and Trial Centers (M-PDTCs) to join the PDTC Research Network (PDXNet) to expand and diversify the PDXNet. These M-PDTCs will develop and conduct pre-clinical testing of models derived from racial/ethnic minority populations.

Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional)

Dr. Tiffany Wallace
240-276-5114

Download Technical Assistance Webinar Slides

Due Dates: June 19, 2019, October 18, 2019, June 19, 2020, and October 18, 2020

Supports feasibility and planning activities to develop translational research programs focused on cancer health disparities research with the expectation that the research programs will become competitive for a full Specialized Programs of Research Excellence (SPORE) award.